Biochemical Assay Core

生化检测核心

• 批准号: 10513868
• 负责人: John Damon Chodera
• 金额: $ 131.53万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10513868
• 关键词: Biochemical; Biological Assay; Structure

A main driver of drug discovery and medicinal chemistry optimization projects is rapid access to quality biochemical activity data of a large number of compounds. Such data facilitates the elucidation of structureactivity relationships and drives decision making in the design-make-test cycle. The Biochemical Assay Core will be in charge of providing the ASAP Center rapid and extensive biochemical assays for the target portfolio. The Core will establish a robust pipeline with the most rigorous assay acceptance criteria. The iterative nature of the activities means that testing of compounds will be performed over an extended time period. Clear protocols and controls are required to enable a high standard of reproducibility. Documentation and quality control will enable the efficient use of resources as compounds and assays are transferred between the interacting groups in the consortium. Access to industry-level automated assays, screening and compound collections provided by the Biochemical Assay Core will be a force multiplier for the ASAP Center in the discovery and development of antiviral drugs.

药物发现和药物化学优化项目的主要驱动力是快速获得质量 大量化合物的生物化学活性数据。这些数据有助于阐明结构反应性 在设计-制造-测试的循环中，生化分析核心将 负责为ASAP中心提供针对目标产品组合的快速和广泛的生化分析。的 核心将建立一个具有最严格试验验收标准的稳健管道。的迭代性质 活动意味着化合物的测试将在较长的时间内进行。明确的协议和 需要控制以实现高标准的再现性。文件和质量控制将使 由于化合物和分析在所述系统中的相互作用组之间转移， 财团获得由美国国家实验室提供的行业级自动化检测、筛选和化合物收集 生化分析核心将成为ASAP中心在发现和开发 抗病毒药物